Phase 1 Study of GSK2315698 in Healthy Japanese Subjects

NCT02953808 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Amyloidosis

Interventions

DRUG: Placebo
DRUG: GSK2315698

Sponsor

GlaxoSmithKline